Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

NORSE EIGHT showed ONS-5010's BCVA improvement of +5.5 letters by week 12, compared to +6.5 letters for ranibizumab. Outlook Therapeutics plans a BLA resubmission for ONS-5010 in Q1 2025, aiming ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks BLA resubmission on track for calendar Q1 2025 Entered into agreements for warrant inducement transaction expected to result in up ...

On Thursday, Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular ...